Cardiff Oncology, Nerviano settle onvansertib rights lawsuit, seek dismissal with prejudice
CRDF•Parties plan dismissal with prejudice
The parties plan to seek dismissal of all claims with prejudice under an amended 2017 exclusive license agreement.
Settlement reached in onvansertib rights dispute
Cardiff Oncology reached a settlement with Nerviano Medical Sciences tied to litigation over global rights to onvansertib.
Both sides agreed to a full mutual release of claims in a U.S. District Court case in the Southern District of California.
Related News
Abundia Global Impact Group outlines waste-to-renewable fuels, chemicals platform in investor presentation
AGIG•
Alto Ingredients management attends H.C. Wainwright Global Investment Conference for investor meetings
ALTO•
